An additional approach for hepatic IR treatment is riligustilide, which upregulates the AMPK-TORC2-FoxO1 axis to attenuate gluconeogenesis in vivo and in vitro, thus preventing hyperinsulinemia and IR [58,59]. Here, CRTC2 is linked to hyperinsulinism.